{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:54:09Z","timestamp":1781639649216,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The current national and international guidelines recommend the use of PSMA imaging in proven BCR including very low levels of PSA (&lt;\u20090.5 ng\/ml), which is associated with a certain rate of false-negative results in regular clinical care. To address this issue, research efforts have focused on improving acquisition protocols via the implementation of delayed images or alternative reconstruction algorithms. One of the mainstays of this approach is the use of standardized reporting systems in regular clinical care and research setting to enhance reliability and reproducibility compared with unstructured confidence assessment. Thus, we aimed to investigate the added benefit of delayed imaging and the utility of reconstruction algorithms for the discrimination of equivocal [\n                      <jats:sup>18<\/jats:sup>\n                      F]PSMA-1007 findings in prostate bed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This monocentric, retrospective study enrolled 36 biologically male patients who underwent dual-time contrast-enhanced [\n                      <jats:sup>18<\/jats:sup>\n                      F]PSMA-1007 PET\/CT scan between October 2021 and February 2024 due to BCR at a tertiary referral hospital. Histopathology after salvage surgery was considered as the gold standard, while clinical, biochemical, and radiological follow-up served as composite reference standards after reviewing the follow-up information. The minimum follow-up per patient was 15 months. The retrospective reading of the early-phase images revealed equivocal PSMA findings, i.e. PSMA-RADS 3\u00a0A, in the prostate bed in 12\/36 patients (33%), with a total median SUV\n                      <jats:sub>max<\/jats:sub>\n                      of 5.1 (3.7\u20136.7). The favourable results with delayed [\n                      <jats:sup>18<\/jats:sup>\n                      F]PSMA-1007 imaging led to upgrading of reporting in 8 out of 12 patients (75%) from PSMA-RADS 3\u00a0A to PSMA-RADS 4\/5.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In conclusion, based upon the study results, we suggest the introduction of a new algorithm to enhance and streamline the imaging decision-process, which would prevent avoidable follow-up scans or further imaging modalities and spare economic resources. Yet, further large-scale studies are warranted to validate the additive effect of this algorithm in regular clinical care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13550-026-01407-x","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T05:24:38Z","timestamp":1772515478000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhancing reader confidence through dual-time imaging and alternative reconstruction algorithms with [18F]PSMA-1007 PET\/CT imaging in local relapsed castration-sensitive prostate cancer?"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1914-1332","authenticated-orcid":false,"given":"Emil","family":"Novruzov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Feisthauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Mattes-Gy\u00f6rgy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Antke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Kuhlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Henke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Cardinale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Boschheidgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Philipp","family":"Radtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Niegisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Albers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Antoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik L.","family":"Giesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduards","family":"Mamlins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"issue":"10","key":"1407_CR1","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s00259-016-3447-9","volume":"43","author":"FL Giesel","year":"2016","unstructured":"Giesel FL, Cardinale J, Sch\u00e4fer M, Neels O, Bene\u0161ov\u00e1 M, Mier W, Haberkorn U, Kopka K, Kratochwil C. (18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. Eur J Nucl Med Mol Imaging. 2016;43(10):1929\u201330. https:\/\/doi.org\/10.1007\/s00259-016-3447-9. Epub 2016 Jun 25. PMID: 27342416; PMCID: PMC4969351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1407_CR2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2967\/jnumed.116.181768","volume":"58","author":"J Cardinale","year":"2017","unstructured":"Cardinale J, Sch\u00e4fer M, Bene\u0161ov\u00e1 M, Bauder-W\u00fcst U, Leotta K, Eder M, Neels OC, Haberkorn U, Giesel FL, Kopka K. Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging. J Nucl Med. 2017;58(3):425\u201331. https:\/\/doi.org\/10.2967\/jnumed.116.181768. Epub 2016 Oct 27. PMID: 27789722.","journal-title":"J Nucl Med"},{"key":"1407_CR3","doi-asserted-by":"publisher","first-page":"362","DOI":"10.2967\/jnumed.118.212233","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, Knorr K, Spohn F, Will L, Maurer T, Flechsig P, et al. Detection efficacy of (18)F-PSMA-1007 PET\/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy. J nuclear medicine: official publication Soc Nuclear Med. 2019;60:362\u20138. https:\/\/doi.org\/10.2967\/jnumed.118.212233.","journal-title":"J nuclear medicine: official publication Soc Nuclear Med"},{"key":"1407_CR4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2967\/jnumed.122.264743","volume":"64","author":"P Olivier","year":"2023","unstructured":"Olivier P, Giraudet A-L, Skanjeti A, et al. Phase III Study of 18F-PSMA-1007 Versus 18F-Fluorocholine PET\/CT for Localization of Prostate Cancer Biochemical Recurrence: A Prospective, Randomized, Crossover Multicenter Study. J Nucl Med Off Publ Soc Nucl Med. 2023;64:579\u201385. https:\/\/doi.org\/10.2967\/jnumed.122.264743.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"1407_CR5","unstructured":"Andsdmedpds. Protocole D\u2019utilisation therapeutique et de Recueil D\u2019informations ABX-PSMA-1007, 1300 MBq\/mL solution injectable, substance active: [18F]PSMA-1007. 2010. http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/extrait.php?specid=64034289. Accessed 02 May 2025."},{"key":"1407_CR6","doi-asserted-by":"publisher","unstructured":"Alberts IL, Seide SE, Mingels C, Bohn KP, Shi K, Zacho HD, Rominger A, Afshar-Oromieh A. Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48(9):2978\u20132989. https:\/\/doi.org\/10.1007\/s00259-021-05210-9. Epub 2021 Feb 6. Erratum in: Eur J Nucl Med Mol Imaging. 2021;48(9):3014\u20133016. doi: 10.1007\/s00259-021-05300-8. PMID: 33550425; PMCID: PMC8263438.","DOI":"10.1007\/s00259-021-05210-9"},{"key":"1407_CR7","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.juro.2006.10.097","volume":"177","author":"MS Cookson","year":"2007","unstructured":"Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D\u2019Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177:540\u20135. https:\/\/doi.org\/10.1016\/j.juro.2006.10.097.","journal-title":"J Urol"},{"key":"1407_CR8","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","volume":"44","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678\u201388. https:\/\/doi.org\/10.1007\/s00259-016-3573-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"1407_CR9","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1007\/s00259-022-05693-0","volume":"49","author":"C Mingels","year":"2022","unstructured":"Mingels C, Bohn KP, Rominger A, Afshar-Oromieh A, Alberts I. Diagnostic accuracy of [18F]PSMA-1007 PET\/CT in biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2022;49(7):2436\u201344. https:\/\/doi.org\/10.1007\/s00259-022-05693-0. Epub 2022 Jan 24. PMID: 35067735; PMCID: PMC9165245.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1407_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1055\/a-1984-8167","volume":"62","author":"A Afshar-Oromieh","year":"2023","unstructured":"Afshar-Oromieh A, Eiber M, Fendler W, Schmidt M, Rahbar K, Ahmadzadehfar H, Umutlu L, Hadaschik B, Hakenberg OW, Fornara P, Kurth J, Neels O, Wester HJ, Schwaiger M, Kopka K, Haberkorn U, Herrmann K, Krause BJ. Deutsche Gesellschaft f\u00fcr Urologie e.\u200aV. (DGU); Deutsche R\u00f6ntgengesellschaft e.\u200aV. (DRG). DGN-Handlungsempfehlung (S1-Leitlinie) \u2013 PSMA-Liganden-PET\/CT in der Diagnostik des Prostatakarzinoms \u2013 Stand: 01\/2022 \u2013 AWMF-Registernummer: 031\u2013055 [Procedure Guideline for Prostate Cancer Imaging with PSMA-ligand PET\/CT]. Nuklearmedizin. 2023;62(1):5\u201319. https:\/\/doi.org\/10.1055\/a-1984-8167. German.","journal-title":"Nuklearmedizin"},{"issue":"1","key":"1407_CR11","doi-asserted-by":"publisher","first-page":"e240091","DOI":"10.1148\/rycan.240091","volume":"7","author":"A Mew","year":"2025","unstructured":"Mew A, Chau E, Bera K, Ramaiya N, Tirumani SH. Recommendations from Imaging, Oncology, and Radiology Organizations to Guide Management in Prostate Cancer: Summary of Current Recommendations. Radiol Imaging Cancer. 2025;7(1):e240091. https:\/\/doi.org\/10.1148\/rycan.240091. PMID: 39792015; PMCID: PMC11791666.","journal-title":"Radiol Imaging Cancer"},{"issue":"5","key":"1407_CR12","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, Cho SY, Fanti S, Giesel FL, Goffin K, Haberkorn U, Jacene H, Koo PJ, Kopka K, Krause BJ, Lindenberg L, Marcus C, Mottaghy FM, Oprea-Lager DE, Osborne JR, Piert M, Rowe SP, Sch\u00f6der H, Wan S, Wester HJ, Hope TA, Herrmann K. PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50(5):1466\u201386. https:\/\/doi.org\/10.1007\/s00259-022-06089-w. Epub 2023 Jan 5. PMID: 36604326; PMCID: PMC10027805.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"1407_CR13","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","volume":"48","author":"F Ceci","year":"2021","unstructured":"Ceci F, Oprea-Lager DE, Emmett L, Adam JA, Bomanji J, Czernin J, Eiber M, Haberkorn U, Hofman MS, Hope TA, Kumar R, Rowe SP, Schwarzenboeck SM, Fanti S, Herrmann K. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021;48(5):1626\u201338. https:\/\/doi.org\/10.1007\/s00259-021-05245-y. Epub 2021 Feb 19. PMID: 33604691; PMCID: PMC8113168.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1407_CR14","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3390\/diagnostics11040665","volume":"11","author":"W Khatri","year":"2021","unstructured":"Khatri W, Chung HW, Werner RA, Leal JP, Pienta KJ, Lodge MA, Gorin MA, Pomper MG, Rowe SP. Effect of Point-Spread Function Reconstruction for Indeterminate PSMA-RADS-3A Lesions on PSMA-Targeted PET Imaging of Men with Prostate Cancer. Diagnostics (Basel). 2021;11(4):665. https:\/\/doi.org\/10.3390\/diagnostics11040665. PMID: 33917238; PMCID: PMC8067967.","journal-title":"Diagnostics (Basel)"},{"key":"1407_CR15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.195255","author":"SP Rowe","year":"2018","unstructured":"Rowe SP, Pienta KJ, Pomper MG, Gorin MA. J Nucl Med. 2018;59(3):479\u201385. https:\/\/doi.org\/10.2967\/jnumed.117.195255. Epub 2017 Sep 8. PMID: 28887401; PMCID: PMC6910634. Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen-Targeted PET Imaging: PSMA-RADS Version 1.0."},{"key":"1407_CR16","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1007\/s00330-023-09516-0","volume":"33","author":"M Bauckneht","year":"2023","unstructured":"Bauckneht M, Miceli A, Signori A, et al. Combined forced diuresis and late acquisition on [68Ga]Ga-PSMA-11 PET\/CT for biochemical recurrent prostate cancer: a clinical practice-oriented study. Eur Radiol. 2023;33:3343\u201353. https:\/\/doi.org\/10.1007\/s00330-023-09516-0.","journal-title":"Eur Radiol"},{"key":"1407_CR17","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s00259-019-04545-8","volume":"47","author":"I Alberts","year":"2020","unstructured":"Alberts I, Sachpekidis C, Gourni E, et al. Dynamic patterns of [68Ga]Ga-PSMA-11 uptake in recurrent prostate cancer lesions. Eur J Nucl Med Mol Imaging. 2020;47:160\u20137. https:\/\/doi.org\/10.1007\/s00259-019-04545-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1407_CR18","doi-asserted-by":"publisher","first-page":"818","DOI":"10.2967\/jnumed.123.266722","volume":"65","author":"LM Unterrainer","year":"2024","unstructured":"Unterrainer LM, Ruchalski K, Allen-Auerbach MS, et al. PSMA PET\/CT Dual-Time-Point Imaging: Nice to Have or Need to Have? J Nucl Med. 2024;65:818\u20139. https:\/\/doi.org\/10.2967\/jnumed.123.266722.","journal-title":"J Nucl Med"},{"key":"1407_CR19","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s00259-018-3989-0","volume":"45","author":"K Rahbar","year":"2018","unstructured":"Rahbar K, Afshar-Oromieh A, B\u00f6gemann M, et al. 18F-PSMA-1007 PET\/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics. Eur J Nucl Med Mol Imaging. 2018;45:1329\u201334. https:\/\/doi.org\/10.1007\/s00259-018-3989-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1407_CR20","unstructured":"Radelumin Schulung f\u00fcr Angeh\u00f6rige der Heilberufe. - Version DE.3.0 - Stand 01\/2024 - Genehmigung 01\/2024. https:\/\/abx.de\/de\/Produkte\/Arzneimittel\/Produktinformation-Radelumin-1. Accessed 03 May 2025."},{"issue":"1","key":"1407_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40658-020-0270-y","volume":"7","author":"JM Rogasch","year":"2020","unstructured":"Rogasch JM, Suleiman S, Hofheinz F, Bluemel S, Lukas M, Amthauer H, Furth C. Reconstructed spatial resolution and contrast recovery with Bayesian penalized likelihood reconstruction (Q.Clear) for FDG-PET compared to time-of-flight (TOF) with point spread function (PSF). EJNMMI Phys. 2020;7(1):2. https:\/\/doi.org\/10.1186\/s40658-020-0270-y. PMID: 31925574; PMCID: PMC6954158.","journal-title":"EJNMMI Phys"},{"issue":"6","key":"1407_CR22","doi-asserted-by":"publisher","first-page":"932","DOI":"10.2967\/jnumed.106.035774","volume":"48","author":"M Soret","year":"2007","unstructured":"Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48(6):932\u201345. https:\/\/doi.org\/10.2967\/jnumed.106.035774. Epub 2007 May 15. PMID: 17504879.","journal-title":"J Nucl Med"},{"issue":"3","key":"1407_CR23","doi-asserted-by":"publisher","first-page":"268","DOI":"10.2967\/jnmt.117.204735","volume":"46","author":"N Hashimoto","year":"2018","unstructured":"Hashimoto N, Morita K, Tsutsui Y, Himuro K, Baba S, Sasaki M. Time-of-Flight Information Improved the Detectability of Subcentimeter Spheres Using a Clinical PET\/CT Scanner. J Nucl Med Technol. 2018;46(3):268\u201373. https:\/\/doi.org\/10.2967\/jnmt.117.204735. Epub 2018 Mar 29. PMID: 29599404.","journal-title":"J Nucl Med Technol"},{"key":"1407_CR24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00259-015-3165-8","volume":"43","author":"G Kuhnert","year":"2016","unstructured":"Kuhnert G, Boellaard R, Sterzer S, et al. Impact of PET\/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis. Eur J Nucl Med Mol Imaging. 2016;43:249\u201358. https:\/\/doi.org\/10.1007\/s00259-015-3165-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1407_CR25","doi-asserted-by":"publisher","unstructured":"Miwa K, Wagatsuma K, Nemoto R, Masubuchi M, Kamitaka Y, Yamao T, Hiratsuka S, Yamaguchi M, Yoshii T, Kobayashi R, Miyaji N, Ishii K. Detection of sub-centimeter lesions using digital TOF-PET\/CT system combined with Bayesian penalized likelihood reconstruction algorithm. Ann Nucl Med. 2020;34(10):762\u2013771. https:\/\/doi.org\/10.1007\/s12149-020-01500-8. Epub 2020 Jul 4. PMID: 32623569.","DOI":"10.1007\/s12149-020-01500-8"},{"issue":"1","key":"1407_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1053\/j.semnuclmed.2023.11.001","volume":"54","author":"AF Voter","year":"2024","unstructured":"Voter AF, Werner RA, Savas H, Gafita A, Ross AE, Gorin MA, Solnes LB, Pomper MG, Rowe SP, Sheikhbahaei S. A Practical Guide to the Pearls and Pitfalls of PSMA PET Imaging. Semin Nucl Med. 2024;54(1):119\u201331. Epub 2023 Nov 18. PMID: 37980186.","journal-title":"Semin Nucl Med"},{"key":"1407_CR27","doi-asserted-by":"crossref","unstructured":"Werner RA, Hartrampf PE, Fendler WP, Serfling SE, Derlin T, Higuchi T, Pienta KJ, Gafita A, Hope TA, Pomper MG, Eiber M, Gorin MA, Rowe SP. Eur Urol. 2023;84(5):491\u2013502. Epub 2023 Jul 4. PMID: 37414701; PMCID: PMC11981304. Prostate-specific Membrane Antigen Reporting and Data System Version 2.0.","DOI":"10.1016\/j.eururo.2023.06.008"},{"key":"1407_CR28","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Krebshilfe D. AWMF): S3-Leitlinie Prostatakarzinom, Langversion 7.0, 2024, AWMF-Registernummer: 043-022OL https:\/\/www.leitlinienprogrammonkologie.de\/leitlinien\/prostatakarzinom\/; Accessed 04 May 2024."},{"key":"1407_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2021;79:263\u201382. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.046.","journal-title":"Eur Urol"},{"issue":"4","key":"1407_CR30","doi-asserted-by":"publisher","first-page":"523","DOI":"10.2967\/jnumed.116.186353","volume":"58","author":"MA Lodge","year":"2017","unstructured":"Lodge MA. Repeatability of SUV in Oncologic 18F-FDG PET. J Nucl Med. 2017;58(4):523\u201332. https:\/\/doi.org\/10.2967\/jnumed.116.186353. Epub 2017 Feb 23. PMID: 28232605; PMCID: PMC5373499.","journal-title":"J Nucl Med"},{"key":"1407_CR31","unstructured":"DATAtab Team. (2025). DATAtab: Online Statistics Calculator. DATAtab e.U. Graz, Austria. URL https:\/\/datatab.net"},{"issue":"Supplement 1","key":"1407_CR32","doi-asserted-by":"publisher","first-page":"S236","DOI":"10.1016\/j.nima.2010","volume":"648","author":"WW Moses","year":"2011","unstructured":"Moses WW. Fundamental Limits of Spatial Resolution in PET. Nucl Instrum Methods Phys Res A. 2011;648(Supplement 1):S236\u201340. https:\/\/doi.org\/10.1016\/j.nima.2010. 11.092. PMID: 21804677; PMCID: PMC3144741.","journal-title":"Nucl Instrum Methods Phys Res A"},{"issue":"2","key":"1407_CR33","first-page":"127","volume":"16","author":"R Sharifpour","year":"2017","unstructured":"Sharifpour R, Ghafarian P, Bakhshayesh-Karam M, Jamaati H, Ay MR. Impact of Time-of-Flight and Point-Spread-Function for Respiratory Artifact Reduction in PET\/CT Imaging: Focus on Standardized Uptake Value. Tanaffos. 2017;16(2):127\u201335. PMID: 29308077; PMCID: PMC5749325.","journal-title":"Tanaffos"},{"issue":"1","key":"1407_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13550-025-01252-4","volume":"15","author":"E Mamlins","year":"2025","unstructured":"Mamlins E, Novruzov E, Watabe T, et al. Biphasic contrast-enhanced [18F]PSMA-1007 PET\/CT imaging to improve the detection of local relapse of prostate cancer. EJNMMI Res. 2025;15(1):61. https:\/\/doi.org\/10.1186\/s13550-025-01252-4. Published 2025 May 30.","journal-title":"EJNMMI Res"},{"key":"1407_CR35","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s00259-019-04552-9","volume":"47","author":"I Alberts","year":"2020","unstructured":"Alberts I, Sachpekidis C, Dijkstra L, et al. The role of additional late PSMA-ligand PET\/CT in the differentiation between lymph node metastases and ganglia. Eur J Nucl Med Mol Imaging. 2020;47:642\u201351. https:\/\/doi.org\/10.1007\/s00259-019-04552-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1407_CR36","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","volume":"44","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, Kesch C, Tolstov Y, Singer S, Grabe N, Duensing S, Sch\u00e4fer M, Neels OC, Mier W, Haberkorn U, Kopka K, Kratochwil C. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44(4):678\u201388. https:\/\/doi.org\/10.1007\/s00259-016-3573-4. Epub 2016 Nov 26. PMID: 27889802; PMCID: PMC5323462.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"1407_CR37","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.2967\/jnumed.117","volume":"58","author":"M Maurits Wondergem, Friso","year":"2017","unstructured":"Maurits Wondergem, Friso M, van der Zant, Remco JJ, Knol SV, Lazarenko. Jan Pruim and Igle J. de Jong. J Nuclear Med November. 2017;58(11):1797\u2013804. https:\/\/doi.org\/10.2967\/jnumed.117.","journal-title":"J Nuclear Med November"},{"issue":"9","key":"1407_CR38","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1007\/s00259-021-05390-4","volume":"48","author":"N Aide","year":"2021","unstructured":"Aide N, Lasnon C, Kesner A, Levin CS, Buvat I, Iagaru A, Hermann K, Badawi RD, Cherry SR, Bradley KM, McGowan DR. New PET technologies - embracing progress and pushing the limits. Eur J Nucl Med Mol Imaging. 2021;48(9):2711\u201326. https:\/\/doi.org\/10.1007\/s00259-021-05390-4. Epub 2021 Jun 3. PMID: 34081153; PMCID: PMC8263417.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Supplement 1","key":"1407_CR39","doi-asserted-by":"publisher","first-page":"S236","DOI":"10.1016\/j.nima.2010.11.092","volume":"648","author":"WW Moses","year":"2011","unstructured":"Moses WW. Fundamental Limits of Spatial Resolution in PET. Nucl Instrum Methods Phys Res A. 2011;648(Supplement 1):S236\u201340. https:\/\/doi.org\/10.1016\/j.nima.2010.11.092. PMID: 21804677; PMCID: PMC3144741.","journal-title":"Nucl Instrum Methods Phys Res A"},{"issue":"1","key":"1407_CR40","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12880-021-00699-w","volume":"21","author":"K Huang","year":"2021","unstructured":"Huang K, Feng Y, Liang W, Li L. Impact of time of flight and point spread function on quantitative parameters of lung lesions in 18F-FDG PET\/CT. BMC Med Imaging. 2021;21(1):169. https:\/\/doi.org\/10.1186\/s12880-021-00699-w. PMID: 34773998; PMCID: PMC8590319.","journal-title":"BMC Med Imaging"},{"issue":"7","key":"1407_CR41","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s00259-013-2391-1","volume":"40","author":"C Lasnon","year":"2013","unstructured":"Lasnon C, Desmonts C, Quak E, Gervais R, Do P, Dubos-Arvis C, Aide N. Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2013;40(7):985\u201396. https:\/\/doi.org\/10.1007\/s00259-013-2391-1. Epub 2013 Apr 6. PMID: 23564036; PMCID: PMC3679414.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-026-01407-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01407-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01407-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:13:57Z","timestamp":1781637237000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13550-026-01407-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1407"],"URL":"https:\/\/doi.org\/10.1186\/s13550-026-01407-x","relation":{"references":[{"id-type":"doi","id":"10.2967\/jnumed.117.195255","asserted-by":"subject"}]},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Declarations"}},{"value":"All procedures performed in studies involving human participants were approved by the ethics committee and carried out in accordance with the ethical standards of the institutional and\/or national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study received approval from the Ethical Committee of the Medical Faculty of Heinrich-Heine University Duesseldorf, Germany (Study-Nr.: 2024\u20132735). Clinical trial number: not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FLG has patent applications for [\n                      18\n                      F]PSMA-1007 and is an advisor at ABX, Telix, and SOFIE Biosciences. GN participated in advisory boards of Novartis. The authors have no relevant financial or nonfinancial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent for participation was obtained from all individual participants included in the study, and the investigation was conducted according to national regulatory laws.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"57"}}